84 related articles for article (PubMed ID: 34328193)
1. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis.
Cao L; Zhou X; Ding X; Gao D
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328193
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1.
Zhou F; Du C; Xu D; Lu J; Zhou L; Wu C; Wu B; Huang J
Mol Med Rep; 2020 Aug; 22(2):1382-1390. PubMed ID: 32468048
[TBL] [Abstract][Full Text] [Related]
3. Ganoderic acid A suppresses autophagy by regulating the circFLNA/miR-486-3p/CYP1A1/XRCC1 axis to strengthen the sensitivity of lung cancer cells to cisplatin.
Gong E; Pan J; Ye Z; Cai X; Zheng H; Yin Z; Jiang Y; Wang X; Cao Z
J Pharm Pharmacol; 2024 Apr; 76(4):354-367. PubMed ID: 38330446
[TBL] [Abstract][Full Text] [Related]
4. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1.
Su C; Cheng X; Li Y; Han Y; Song X; Yu D; Cao X; Liu Z
Cancer Med; 2018 Jun; 7(6):2485-2503. PubMed ID: 29663730
[TBL] [Abstract][Full Text] [Related]
6. miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
Huang T; Ren K; Ding G; Yang L; Wen Y; Peng B; Wang G; Wang Z
Oncol Rep; 2020 Jun; 43(6):1906-1914. PubMed ID: 32186774
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma.
Li QY; Guo Q; Luo WM; Luo XY; Ji YM; Xu LQ; Guo JL; Shi RS; Li F; Lin CY; Zhang J; Ke D
Aging (Albany NY); 2024 Jan; 16(1):66-88. PubMed ID: 38170222
[TBL] [Abstract][Full Text] [Related]
8. Polyphyllin II (PPII) Enhances the Sensitivity of Multidrug-resistant A549/DDP Cells to Cisplatin by Modulating Mitochondrial Energy Metabolism.
Peng L; Yang R; Wang Z; Jian H; Tan X; Li J; He Z; Huang R; Zeng P; Gao W
In Vivo; 2024; 38(1):213-225. PubMed ID: 38148070
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.
Wu JE; Wu YY; Tung CH; Tsai YT; Chen HY; Chen YL; Hong TM
Theranostics; 2020; 10(19):8903-8923. PubMed ID: 32754286
[TBL] [Abstract][Full Text] [Related]
10. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma.
Shi K; Li QY; Zhang YQ; Huang H; Ding DX; Luo WM; Zhang J; Guo Q
Aging (Albany NY); 2023 Oct; 15(20):11067-11091. PubMed ID: 37899135
[TBL] [Abstract][Full Text] [Related]
11. Kynureninase knockdown inhibits cisplatin resistance in vivo and in vitro and impacts the prognosis of cervical adenocarcinoma.
Zhang JW; Wang YN; Zhong ML; Liang MR
Cell Div; 2023 Sep; 18(1):15. PubMed ID: 37742026
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma.
Son SM; Yun J; Kim DW; Jung YS; Han SB; Lee YH; Han HS; Woo CG; Lee HC; Lee OJ
BMC Cancer; 2023 Sep; 23(1):843. PubMed ID: 37684602
[TBL] [Abstract][Full Text] [Related]
13. Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin.
Ghetti M; Vannini I; Storlazzi CT; Martinelli G; Simonetti G
Mol Cancer; 2020 Mar; 19(1):69. PubMed ID: 32228602
[TBL] [Abstract][Full Text] [Related]
14. TFAP4 promotes the growth of prostate cancer cells by upregulating FOXK1.
Gu Y; Jiang J; Liang C
Exp Ther Med; 2021 Nov; 22(5):1299. PubMed ID: 34630654
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of O-propargyllawsone in A549 lung adenocarcinoma cells.
Dos Santos EWP; de Sousa RC; de Franca MNF; Santos JF; Ottoni FM; Isidório RG; de Lucca Junior W; Alves RJ; Scher R; Corrêa CB
BMC Complement Med Ther; 2023 Sep; 23(1):333. PubMed ID: 37730601
[TBL] [Abstract][Full Text] [Related]
16. KLF9‑regulated FBXO31 inhibits the progression of endometrial cancer and enhances the sensitivity of endometrial cancer cells to cisplatin.
Yang M; Niu C
Exp Ther Med; 2024 Feb; 27(2):54. PubMed ID: 38234628
[TBL] [Abstract][Full Text] [Related]
17. Expression and role of FKBPL in lung adenocarcinoma.
She L; Zhang X; Shen R; He S; Miao X
J Cancer; 2024; 15(1):166-175. PubMed ID: 38164287
[TBL] [Abstract][Full Text] [Related]
18. Retraction Note: Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21.
Yang Q; Zhang Z; Xu H; Ma C
Mol Cell Biochem; 2024 Mar; 479(3):737. PubMed ID: 38407732
[No Abstract] [Full Text] [Related]
19. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating
Wang X; Wang H; Jiang H; Qiao L; Guo C
Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285
[No Abstract] [Full Text] [Related]
20. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
